Published online Mar 18, 2024. doi: 10.5312/wjo.v15.i3.266
Peer-review started: December 4, 2023
First decision: December 17, 2023
Revised: December 21, 2023
Accepted: January 23, 2024
Article in press: January 23, 2024
Published online: March 18, 2024
Processing time: 102 Days and 1.1 Hours
Multitudinous advancements have been made to the traditional microfracture (MFx) technique, which have involved delivery of various acellular 2nd generation MFx and cellular MFx-III components to the area of cartilage defect. The relative benefits and pitfalls of these diverse modifications of MFx technique are still not widely understood.
To comparatively analyze the functional, radiological, and histological outcomes, and complications of various generations of MFx available for the treatment of cartilage defects.
A systematic review was performed using PubMed, EMBASE, Web of Science, Cochrane, and Scopus. Patients of any age and sex with cartilage defects under
Forty-four RCTs were included in the analysis with patients of mean age of 39.40 (± 9.46) years. Upon comparing the results of the other generations with MFX-I as a constant comparator, we noted a trend towards better pain control and functional outcome (KOOS, IKDC, and Cincinnati scores) at the end of 1-, 2-, and 5-year time points with MFx-III, although the differences were not statistically significant (P > 0.05). We also noted statistically significant Magnetic resonance observation of cartilage repair tissue score in the higher generations of microfracture (weighted mean difference: 17.44, 95% confidence interval: 0.72, 34.16, P = 0.025; without significant heterogeneity) at 1 year. However, the difference was not maintained at 2 years. There was a trend towards better defect filling on MRI with the second and third generation MFx, although the difference was not statistically significant (P > 0.05).
The higher generations of traditional MFx technique utilizing acellular and cellular components to augment its potential in the management of cartilage defects has shown only marginal improvement in the clinical and radiological outcomes.
Core Tip: Chondral lesions have been reported in 60% of patients undergoing arthroscopic procedures of the knee; and such defects are described as one of the leading causes of chronic knee pain. As compared with the other cartilage restoration strategies, microfracture (MFx) is relatively cost-effective, simple, minimally-invasive and may also be performed in a single stage. Nevertheless, recent studies have demonstrated that modifications of the traditional MFx technique, such as the use of synthetic and autologous biological adjuvants may enhance the repair tissue quality, resilience, and overall efficacy of the procedure. Based on the current network meta-analysis we could conclude that the use of acellular and cellular adjuvants has shown only marginal improvement in the clinical (pain and functional scores) and radiological outcome in patients undergoing microfracture for cartilage defects of the knee. The safety and efficacy of the higher generation MFx procedures are also clearly evident from our review. However, there is a substantial potential for further improvement in the cellular components (chondrocytes over other cellular lineage), culture or processing methodology, delivery modalities (including appropriate scaffolds); as well as better surgical techniques to achieve demonstrable significant outcome improvement.